Duarte, CA Clinical Trials Report — July 2026

People in Duarte who may qualify for a clinical trial should act promptly: 22 recruiting studies are expected to close within the next 90 days. None of these closing studies accepts healthy volunteers, so patients with relevant cancer or blood disorders are the group most likely to benefit from contacting local research teams now. Duarte currently has 548 recruiting trials across 81 research facilities.

July brought 10 new studies, up from 7 in May 2026 but below the 20 that opened in June. The city’s research activity is centered heavily at City of Hope facilities, giving Duarte residents unusually direct access to oncology and hematology research.

Closing windows for Duarte patients

The largest group of closing-soon studies involves kidney cancer, particularly advanced or metastatic clear cell disease. Breast cancer and multiple myeloma also appear repeatedly among studies nearing their projected closing dates:

• Stage III renal cell cancer, AJCC v8 (2 trials)
• Advanced clear cell renal cell carcinoma (2 trials)
• Metastatic clear cell renal cell carcinoma (2 trials)
• Solid tumors (2 trials)
• Stage IV renal cell cancer, AJCC v8 (2 trials)
• Multiple myeloma (2 trials)
• Anatomic stage IV breast cancer, AJCC v8 (2 trials)
• Metastatic breast carcinoma (2 trials)
• Cervical cancer (1 trial)
• Estrogen receptor-positive breast carcinoma (1 trial)

Projected closing dates are not guarantees: enrollment can end earlier if a study reaches its participant target. Patients with one of these diagnoses should review trial requirements, confirm that Duarte is an active location, and contact the study team soon. There are 32 trials recruiting healthy volunteers in Duarte overall, but 0 of the closing-soon studies include healthy participants.

New July studies span blood cancers, breast cancer, and solid tumors

The July openings include 6 drug trials, 5 studies classified as other, 3 procedures, 1 behavioral study, and 1 biological study. New condition categories include acute myeloid leukemia, aplastic anemia, bone marrow failure syndromes, atrial fibrillation, bone neoplasm, breast carcinoma, chronic graft-versus-host disease, chronic lymphocytic leukemia, and other hematologic cancers.

• NCT07702578 is a Phase 3 study sponsored by TScan Therapeutics, Inc. evaluating T-cell receptor-engineered donor T cells after allogeneic peripheral blood stem cell transplantation. The planned enrollment is 310 participants.
• NCT07700160 is a first-in-human Phase 1/Phase 2 study from VelaVigo Bio Inc. for participants with advanced malignant solid tumors. The study plans to enroll 230 participants while researchers assess dosing, safety, and early activity.
• NCT07711327, sponsored by Tina Baykaner, examines how often atrial fibrillation occurs in people with blood cancers starting Bruton's tyrosine kinase inhibitor therapy. The study lists 500 planned participants.
• NCT07690852, sponsored by City of Hope Medical Center, studies patient and provider views on environmental exposure assessments in breast cancer care. It includes female patients at average or high risk for breast cancer and those diagnosed with early-onset breast cancer, with 423 planned participants.

AstraZeneca, Cullinan Therapeutics Inc., TScan Therapeutics, VelaVigo Bio Inc., and Dren Bio are among the industry sponsors opening studies locally. Five new trials are categorized as industry-sponsored and five as other. City of Hope Medical Center sponsors 4 of the new studies, making it the most active named sponsor in July.

City of Hope dominates local access

Duarte’s research landscape is concentrated at a group of City of Hope locations. City of Hope Medical Center lists 152 recruiting trials, followed by City of Hope with 129 and City of Hope Comprehensive Cancer Center with 95. These sites are especially relevant for people seeking cancer, blood-cancer, transplant, and investigational drug studies.

• City of Hope Medical Center (152 trials)
• City of Hope (129 trials)
• City of Hope Comprehensive Cancer Center (95 trials)
• City of Hope National Medical Center (42 trials)
• Research Site (25 trials)
• City of Hope National Medical Center and City of Hope Medical Center (11 trials)
• City of Hope - Duarte Cancer Center (6 trials)
• City of Hope Cancer Center (6 trials)
• City of Hope - Duarte (4 trials)
• City of Hope Investigational Drug Services (3 trials)

Because several listings may represent related departments or campus locations, participants should verify the exact site and study contact before scheduling a visit. Still, the concentration of listings makes City of Hope the clearest starting point for Duarte residents, particularly those seeking oncology or hematology research.

Who can participate this month?

Only 1 of the 10 new July studies accepts healthy volunteers, while 32 healthy-volunteer trials are recruiting across Duarte in total. The new-study group includes 0 trials that include children, 1 female-only study, and 10 that include older adults. No new study is male-only.

Healthy adults should search the broader Duarte listings rather than focusing only on July openings. Patients with acute myeloid leukemia, aplastic anemia, breast cancer, kidney cancer, multiple myeloma, chronic lymphocytic leukemia, transplant-related conditions, or solid tumors have more condition-specific reasons to act quickly, especially where a study is approaching its closing window.

California alternatives for people willing to travel

Duarte has more recruiting trials than the other California cities listed in the data. Nearby options include Los Angeles with 25 trials, San Francisco with 22, San Diego with 16, Palo Alto with 10, La Jolla and Sacramento with 8 each, and Stanford and Anaheim with 7 each. Traveling may expand eligibility options when a Duarte study requires a diagnosis, treatment history, or age range that does not fit.

With new openings continuing after the June peak and several kidney, breast, and blood-cancer studies nearing closure, Duarte participants should monitor listings throughout August. Earlier contact gives research teams more time to review records, complete screening, and determine whether a local study remains available.